// App-Quantinova.ai

e11518 : Clinical validation of the Prosigna breast cancer prognostic gene signature assay on formalin-fixed paraffin embedded breast cancer tumors with comparison to standard molecular markers.

Researchers

Presenter

  • Roy R. L. Bastien

Principal Investigators

  • Cecily Vaughn

  • Danielle Elsberry

  • Inge J. Stijleman

  • Philip Seth Bernard

Medical Centers

  • University of Utah Health Sciences Center, Salt Lake City, UT

  • Department of Pathology, University of Utah Health Sciences Center/HCI, Salt Lake City, UTARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UTThe ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Solid malignancies

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • N/A

Outcome

  • Positive

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved